What it's for (Indications)
- Brimonidine tartrate ophthalmic solution is a topical alpha-adrenergic agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
- It can be used as monotherapy in patients who require lowering of IOP or as adjunctive therapy when other IOP-lowering medications are insufficient.
- Its efficacy stems from its ability to decrease aqueous humor production and enhance uveoscleral outflow, thereby contributing to the maintenance of ocular health and prevention of progressive optic nerve damage associated with elevated IOP.
- This therapeutic intervention is crucial for managing chronic ocular conditions that, if left untreated, can lead to irreversible vision loss and blindness.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage for brimonidine tartrate ophthalmic solution typically involves instilling one drop into the affected eye(s) three times daily, approximately every 8 hours. The specific concentration (e.g., 0.1%, 0.15%, or 0.2%) may vary based on the formulation and physician's discretion, with the 0.2% concentration often prescribed twice daily due to its extended duration of action. Patients should be instructed to apply the drops carefully, avoiding contact of the dropper tip with the eye or surrounding structures to prevent contamination. If more than one topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart. Adherence to the prescribed dosing regimen is critical for achieving optimal therapeutic effect and maintaining consistent intraocular pressure reduction throughout the day. |
Safety & Warnings
Common Side Effects
- Commonly reported side effects of brimonidine tartrate ophthalmic solution include ocular discomfort such as burning, stinging, or foreign body sensation upon instillation, ocular hyperemia (redness), blurred vision, and ocular pruritus (itching).
- Systemic side effects can include dry mouth, somnolence (drowsiness), and fatigue.
- Less frequently, patients may experience allergic conjunctivitis, follicular conjunctivitis, eyelid edema, headache, or dizziness.
- Serious but rare adverse events could involve cardiovascular effects like hypotension or bradycardia, or severe systemic allergic reactions.
- Patients should be advised to contact their healthcare provider if any side effects become severe or persistent, or if they experience any signs of an allergic reaction or significant changes in vision or systemic health.
Serious Warnings
- Black Box Warning: SERIOUS WARNINGS: POTENTIAL FOR SEVERE SYSTEMIC EFFECTS IN INFANTS AND YOUNG CHILDREN Brimonidine tartrate ophthalmic solution is CONTRAINDICATED in neonates and infants, particularly those under 2 years of age, due to the significant risk of severe and potentially life-threatening systemic adverse reactions. These reactions include profound central nervous system (CNS) depression, which can manifest as somnolence, lethargy, loss of consciousness, and coma. Additionally, severe respiratory depression, apnea (temporary cessation of breathing), bradycardia (slow heart rate), and hypotension (low blood pressure) have been reported in this vulnerable population. These events have necessitated hospitalization and intensive care support, and in rare cases, have been associated with fatal outcomes. The systemic absorption of brimonidine, even at low ophthalmic doses, can lead to dangerously high plasma concentrations in infants and young children due to their immature blood-brain barrier and metabolic pathways. Therefore, careful consideration of age is paramount, and alternative treatments should be sought for infants and young children to avoid these severe risks. This warning emphasizes the critical importance of avoiding use in this specific age group.
- Brimonidine tartrate ophthalmic solution should be used with caution in patients with severe cardiovascular disease, including those with cardiac insufficiency, uncontrolled hypertension, or a history of significant cerebrovascular disease due to the potential for systemic absorption leading to clinically significant decreases in blood pressure or heart rate.
- Caution is also advised in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, thromboangiitis obliterans, or orthostatic hypotension.
- Systemic alpha-2 adrenergic agonists are known to reduce blood pressure and pulse rate.
- Although ophthalmic brimonidine has minimal systemic effects in most adults, the potential for systemic absorption exists, particularly with over-application.
- Patients should be monitored for signs of systemic hypotension or central nervous system depression, especially if concurrently using other CNS depressants or antihypertensive agents.
How it Works (Mechanism of Action)
Brimonidine tartrate is a highly selective alpha-2 adrenergic receptor agonist. Its primary mechanism of action in reducing intraocular pressure involves a dual effect on aqueous humor dynamics. Firstly, it significantly decreases the production of aqueous humor, the fluid that fills the anterior and posterior chambers of the eye, by acting on the ciliary body. Secondly, it enhances the uveoscleral outflow, which is an alternative pathway for aqueous humor drainage from the eye. These combined actions lead to a notable reduction in intraocular pressure. The selectivity of brimonidine for alpha-2 receptors compared to alpha-1 receptors contributes to its favorable safety profile by minimizing vasoconstrictive effects on ocular blood vessels and reducing systemic side effects associated with non-selective alpha-agonists.
Commercial Brands (Alternatives)
No other brands found for this formula.